Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Prostatic Neoplasms
  • Testosterone

abstract

  • The undetectable PSA end point allows for a rapid screening of interventions for further study. Increasing the number of docetaxel cycles after a shorter period of testosterone repletion, and a longer duration of testosterone depletion, increased the proportion of men who achieved an undetectable PSA. The higher-than-expected incidence of febrile neutropenia may have been related to the reduced overall docetaxel clearance in patients with noncastrate versus castrate testosterone levels.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3051836

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.15.1928

PubMed ID

  • 18565882

Additional Document Info

start page

  • 2959

end page

  • 65

volume

  • 26

number

  • 18